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The recent approval of several agents have revolutionized the scenario of therapeutic
management of metastatic renal cell carcinoma (RCC) allowing us to reach important
clinical end points with extended patients’ survival. Actually, every new drug approved
has represented an important step forward to the improvement of patient’s survival.
On the other hand, we now understand that RCC includes a large group of tumor
entities, each of them with different genetic and mutational alterations, but also showing
different clinical behavior; a reason behind the needs of subtype specific personalized
approach to therapy of RCC. Immunotherapy is gradually becoming a key factor in the
therapeutic algorithm for patients with locally advanced or metastatic RCC. Due to the
combination of potent treatment success and potentially deadly adverse effects from
immune checkpoint inhibitors (ICI), gathering prognostic and predictive information about
FDA-indicated tumors seems to be prudent. Robust and reliable biomarkers are crucial
for patient’s selection of treatments with immunomodulatory drugs. PD-L1 expression is
a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1
inhibitors in a variety of tumor types including RCC. Each FDA approved PD-1/PD-L1
drug is paired with a PD-L1 Immunohistochemistry (IHC) assay. Thus, there is need for
improved knowledge and application of PD-1/PD-L1 IHC biomarkers in daily practice.
IHC staining appears in membranous fashion. The atezolizumab approved IHC assay
is unique in that only immune cell staining is quantified for the use of this assay in
RCC. A single biomarker for patient selection may not be feasible, given that immune
responses are dynamic and evolve over time. Biomarker development for ICI drugs will
likely require integration of multiple biologic components like PD-L1 expression, TILs and
mutational load. New methodological approaches based on digital pathology may be
relevant since they will allow recognition of the biomarker and to objectively quantitate its
expression, and therefore might produce objective and reproducible cut-off assessment.
Multidisciplinary approach is very much needed to fully develop the current and future
value of ICI in clinical practice.
Keywords: renal cell carcinoma, PD-L1, immunotherapy, RCC subtypes, immunological biomarker, predictive
biomarker, tumor mutation load
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INTRODUCTION
The recent approval of several agents have revolutionized the
scenario of therapeutic management of metastatic renal cell
carcinoma (RCC) allowing us to reach important clinical end
points with extended patients’ survival (1).
The first generation of immune checkpoint inhibitors
(anti-CTLA-4 and anti-PD-1/PD-L1) targeted natural immune
homeostasis pathways to drive anti-tumor immune responses.
These agents led to unprecedented results in patients with
previously incurable metastatic disease and therefore became
first-line therapies for some advanced cancers (2–12). Since
these agents are efficacious in only a minority of patients,
however, newer strategies are becoming available that target
additional immunomodulatory mechanisms to activate patients’
own anti-tumor immune responses. Emerging targets include co-
inhibitory and co-stimulatory markers of the innate and adaptive
immune system.
In this review, we will discuss: (1) Pathologic and molecular
subtypes of RCC; (2) Current landscape of targeted therapy
in renal cell carcinoma; (3) Overview of immunotherapy in
renal cell carcinoma; (4) Predictive immunological biomarkers
in renal cell carcinoma; (5) Gene expression as predictive
biomarkers in renal cell carcinoma; (6) The current status of PD-
L1 immunohistochemistry; (7) MMR-deficiency and mutational
load in RCC; and (8) Biomarkers of acquired resistance. Finally,
we briefly highlight likely future perspectives of predictive
biomarkers of immunotherapy in RCC.
PATHOLOGIC AND MOLECULAR
SUBTYPES OF RENAL CELL CARCINOMA
Clear cell RCC (ccRCC) accounts for about 75% of kidney
cancer while the other 25% are classified as non-clear cell
renal cell carcinoma (nccRCC) (13). Over a dozen pathological
subtypes are now recognized by the most recent World
Health Organization classification of Tumors of the Urinary
System and Male Genital Organs (13). These subtypes include
papillary renal cell carcinoma (pRCC) (20%) and chromophobe
renal cell carcinoma (chRCC) (5%), which are the most
frequent nccRCC subtypes; hereditary leiomyomatosis and renal
cell associated -carcinoma, collecting duct carcinoma, renal
medullary carcinoma, MiT family translocation carcinoma,
succinate dehydrogenase-deficient RCC, mucinous tubular and
spindle cell carcinoma, tubulocystic RCC, Acquired cystic
disease-associated RCC, clear cell papillary RCC, and RCC
unclassified represent less common subtypes (13).
Several genomic changes have been found in ccRCC, mostly
epigenetic reprogramming and oncogenic metabolism pathways
alterations (13–18) with other common genetic changes in
genes controlling cellular oxygen pathway (e.g., VHL) and
the maintenance of chromatin structure (e.g., PBRM1) (19–
22). TCGA analysis of a ccRCC cohort found similar genomic
changes and reported recurrent alterations in the PI(3)K/AKT
pathway and several epigenetic changes in DNA methylation
(22). Molecular stratification of ccRCC revealed 2 different
subtypes: clear cell type A (ccA) and B (ccB), with ccA patients
having a markedly better prognosis (23, 24). A second TCGA
study focussed on papillary RCC (pRCC) and found that type
1 and type 2 pRCC are distinctly different diseases based on
molecular features and that type 2 pRCC is a heterogeneous
disease with at least three different subgroups (25). A third TCGA
project focussed on the chromophobe RCC (ChRCC) and found
gene expression changes related to mitochondrial function and
recurrent structural breakpoints within TERT promoter region
(26). Recently, a multilevel molecular characterization of the
3 TCGA RCC databases revealed nine major genomic RCC
subtypes, each one being distinct in terms of altered pathways and
patient survival (16). Overlapping and subtype-specific genomic
changes were observed, and good correlation with histologic
subtypes was noticed. These molecular classes show substantial
molecular diversity represented within each major histologic
type, but importantly, actionable alterations also included PI3K
and immune checkpoint pathways (16).
CURRENT LANDSCAPE OF TARGETED
THERAPY IN RENAL CELL CARCINOMA
The better knowledge of molecularly altered pathways of RCC
has led to the development of new classes of drugs rising
the targeting therapy era (1, 12, 16–23, 27). Angiogenesis, the
hallmark of RCC, is the final target of several TKi (Sunitinib,
Axitinib, Sorafenib and pazopanib) (1–12). After angiogenesis,
the finding that, the deregulation of the PI3K–Akt–mTOR
pathway, activated at different levels of the signaling cascade,
drives RCC progression has led to the development of the
mTOR inhibitors everolimus and temsirolimus. The association
between everolimus and lenvatinib (a VEGFR1, VEGFR2 and
VEGFR3 FGFR1, FGFR2, FGFR3, FGFR4, PDGFR, RET and KIT
inhibitor) has been recently explored in a phase II clinical trial
which demonstrated a better progression free survival (PFS) for
patients receiving the combination of these two drugs compared
to those who received everolimus monotherapy (10). Recently,
also the mesenchymal-epithelial transition and multi-tyrosine
kinases inhibitor cabozantinib has been included in clinical
practice (1–12).
These drugs have led to an improvement in overall survival
(OS) (sunitinib, pazopanib, cabozantinib, temsirolimus) and
PFS (sunitinib, axitinib, cabozantinib, sorafenib, pazopanib,
everolimus and temsirolimus) showing a safety profile with a
remarkable clinical activity in a disease which has always been
poor of active treatments (12, 15).
OVERVIEW OF IMMUNOTHERAPY IN
RENAL CELL CARCINOMA
Targeting drugs have significantly changed the course of RCC,
but it’s likely that a new classes of agents, the immune-checkpoint
inhibitors (ICI), are destined to feed this new paradigm in RCC
treatment (12, 28–51).
Programmed Death Receptor 1/Programmed Death Receptor
Ligand 1 (PD 1/PD-L1) and Cytotoxic T Lymphocytes Antigen 4
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(CTLA-4) inhibitors are agents able to target specific pathways
related to immune-response which are often hyper-activated
by tumor cell interaction (46). By inhibition of these targets,
ICI could reactivate a specific immune response against tumor
cells (Figure 1) (52). The observation that, RCC is related to
a high mutation burden and so maybe to a high antigens
expression, has led to test these drugs in different stages
of the disease. Checkmate 025 was the first large phase III
clinical trials comparing the PD-1 inhibitor nivolumab to
everolimus in patients with locally advanced or metastatic
RCC progressed to at least one VEGF/VEGFR inhibitor (11).
This study met its primary endpoints showing an OS benefit
in patients receiving nivolumab. Furthermore, patients treated
with immunotherapy showed a higher overall response rate
(ORR) compared to everolimus with an important percentage
of patients achieving long lasting response (11). It is not
surprising that the important results achieved in this trial have
move to explore immunotherapy in other setting, such as
adjuvant/neo-adjuvant stage and as first line therapy (12). Two
different strategies been adopted: (1) the combination between
an immune-checkpoint inhibitor and a VEGF inhibitor has
been evaluated in a phase II trials. Indeed, in Immotion150
305 patients with locally advanced/mRCC and untreated RCC
were randomized to receive: atezolizumab (an anti PD-L1
inhibitor) and bevacizumab, atezolizumab alone or sunitinib
(41). The association arm resulted in a longer PFS compared
to atezolizumab (6.1 months) and sunitinib arms with a higher
percentage of ORR in combination arm (41). Of note, patients
with PD-L1 positive expression (≥1%) showed a longer PFS
(14.7 months) and higher ORR (46%) in atezolizumab arm;
(14) and (2) the combination between two immune-checkpoint
inhibitors have been recently tested in a large phase III trial:
The Checkmate 214. In this study patients were randomized to
receive the nivolumab (anti PD-1) and Ipilimumab (Anti CTLA
4) combination or sunitinib as first line therapy (42). In ESMO
2017, Escudier et al. (42) presented primary results after 17.5
months of follow up showing that the combination between
ipilimumab-nivolumab resulted in higher ORR and complete
response rate in intermediate/poor risk patients. Of note, patients
with intermediate/poor risk disease and PD-L1 expression ≥1%
showed higher ORR and PFS compared to sunitinib, while
patients with favorable category of risk (showing lower PD-
L1 expression) displayed a longer PFS and a higher ORR with
sunitinib (42) (Table 1).
These encouraging results suggest that we are about to enter
a new era for the management of metastatic RCC since the
data provided from these trials might represent only the tip of
the iceberg, and therefore, we could expect more therapeutic
novelties to come. Nonetheless, even if immunotherapy provides
a new hope for patients with metastatic RCC, the “old” targeting
therapy is far from being abandoned. Indeed, Checkmate
025 showed that nivolumab is better than everolimus, but
there are other agents showing to be extremely effective after
VEGF/VEGFR inhibitors progression, thus, the decision of
second line treatment should be weighted on the basis of the
clinical outcome pursued as well as patient preference and
toxicity profile (53). Though in first line setting immunotherapy
showed interesting results, it’s probably that the positive effect
could be restricted to patients with specific clinical features, such
as intermediate/poor risk disease while patients with favorable
profile could benefit from a standard therapeutic approach (46).
It is probably that the worst clinical profile of the disease could
be related to a high mutational burden of tumor cells, therefore
resulting in a higher antigens expression. Preliminary data seems
to indicate that these patients with high mutational load present
a higher percentage of tumors with positive PD-L1 expression.
Future studies will help us to better understand the role of PD-
L1 as prognostic and predictive response factor since to date
we have highly diverging information. Indeed, a meta-analysis
of six published studies revealed that a higher level of PD-L1
expression increased the risk of death by representing therefore a
negative prognostic factor (44). Differently to what was expected,
the improved OS with nivolumab was not correlated with PD-
L1 expression in Checkmate 025 while patients with positive
PD-L1 expression seems to show more clinical benefit from
immune-checkpoint inhibitors in Immotion150 and Checkmate
214 (Table 2).
PREDICITVE IMMULOGICAL
BIOMARKERS IN RENAL CELL
CARCINOMA
Due to the increasing role of immunotherapy in clinical practice,
the research of predictive response factors remains a critical
but still unmet issue. A PD-L1 assessment on tumor cells
through Dako PD-L1 IHC 28-8 pharmDx test was performed
in both the Checkmate 025 and 214 trials. In Checkmate 025
nivolumab efficacy was not influenced by PD-L1 expression.
However, patients expressing PD-L1 more than 1% (n = 181)
showed a worse OS in both treatment arms thus suggesting
a prognostic role more than a predictive one. On the other
hand, an exploratory analysis of the Checkmate214 showed a
PFS benefit favoring combination only in patients expressing
PD-L1 (1% or greater). Survival and ORR advantages were
maintained in all PD-L1 categories. However, patients with
higher PD-L1 expression showed greater benefit with the
immune-combination. Taking together, these results seem to
confirm that PD-L1 IHC expression does not act as predictor
of response in patients with metastatic ccRCC receiving ICI
immunotherapy (12, 15, 28, 46, 54). Furthermore, intratumoral
eterogeneity of PD-L1 expression is another issue to take into
consideration. As demonstrated by López et al. a multisite tumor
sampling strategy identified a greater number of positive cases
compared to current tumor sampling protocols and a different
pattern of PD-L1 expression with positive and negative regions
in the same tumor (55).
As seen in other neoplastic diseases in which immunotherapy
has been successfully tested, tumor mutational burden and non-
synonymous mutation expression have been related to higher
neo-antigens tumor expression and to favorable immunotherapy
response. A rationale supporting additional research of this
variable in RCC derives from the evidence that immunotherapy
is associated to higher clinical benefit in worst risk categories of
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FIGURE 1 | “Mechanism of action of immune checkpoint inhibitors. PD-1 is expressed on activated T cells and when it binds to its ligand PD-L1 on tumor cells leads
to T cell exhaustion. CTLA-4 competes with CD28 (costimulatory T cell molecule) for B7 ligands (CD80 and CD86 that are not shown in the figure) and upon activation
decreases T cell proliferation as well as activity. Blockade of CTLA-4 (by anti-CTLA-4) and PD-1 (anti-PD-1) or PD-L1 stimulates effector T cells to produce antitumor
responses. PD-1, programmed death-1; PD-L1, programmed death-ligand 1; MHC, major histocompatibility complex; TCR, T cell receptor; and CTLA-4, cytotoxic T
lymphocyte antigen.” Reproduced from Raman and Vaena (52). Available via license: CC BY 3.0.
TABLE 1 | Results obtained in selected trials exploring immune check point inhibitors in metastatic/locally advanced RCC using different combination of drugs.
Study name with
experimental and
comparator arms
Setting N
ITT
N
PD-L1+
OS
ITT
HR OS
PD-L1+
PFS
ITT
HR PFS
PD-L1+
HR ORR
ITT
ORR
PD-L1+
CR
IMMOTION150
Atezolizumab +
Bevacizumab
Untreated patients with
locally advanced or
metastatic renal cell
carcinoma
101 164 NR NR NR NR NR NR NR 32% 46% NR
Atezolizumab 103 NR NR NR NR 25% 28% NR
Sunitinib 101 NR NR NR NR 29% 27% NR
CHECKMATE 214
Ipilimumab +
Nivolumab
Untreated patients with
locally advanced or
metastatic renal cell
carcinoma
550 204 NR NR NR 11.6 0.82 22.8* 0.48 NR 58%* 9.4%*
Sunitinib 546 224 NR NR NR 8.4 5.9* NR 25%* 1.2%*
NR, not reported; PFS: progression free survival; OS, overall survival; ORR, overall response rate; CR, complete response. *Intermediate/poor risk patients with PD-L1 expression ≥1%.
RCC, a clinical category of RCC in which high mutational load
is present (30–32). Indeed, considering the subgroup analysis of
the Checkmate 025 study and the significantly better results of
nivolumab-ipilimumab combination in intermediate/poor risk
patients in the Checkmate 214, it seems likely that tumors
with worst clinical features are those that better respond
to immune-checkpoint inhibitors and this may be due to a
higher mutational load resulting in higher neo-antigen content.
Unfortunately, differently than expected, mutational load does
not seem to correlate with MSKCC or IMDC prognostic criteria
(31). Moreover, no difference has been observed between clear
cell and sarcomatoid components of different tumor samples,
suggesting that the level of mutational load is not a variable
associated to worst clinical features of the disease, hypothesis that
clearly needs further investigation (33).
Concerning the correlation between mutational burden and
response to ICI immunotherapy in ccRCC, de Velasco et al.
carried out a whole exomes and transcriptomes sequencing
of 9 patients with metastatic RCC receiving nivolumab. They
discovered that RCC had relatively few non-synonymous
mutations and neo-antigens and, surprisingly, that among
patients receiving nivolumab non-synonymous mutations were
significantly higher in non-responder patients (n = 6) compared
to responder patients (n = 3) (34). Of note, they found a
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TABLE 2 | Summary of assays and response rates in immune checkpoint inhibitor
trials.
Drug Antiboy for
PD-L1 IHC assay
Definition of
PD-L1 positivity
Nivolumab (SA) PD-1 Rabbit 28-8 (Dako) PD-L1 ≥5% (TC)
Atezolizumab (SA) PD-L1 Rabbit SP142
(Ventana)
IHC 1/2/3 (IC)
Nivolumab/
Ipilimumab(C)
PD-1/CTLA-4 Rabbit 28-8 (Dako) PD-L1 ≥1% (TC)
Atezolizumab/
Bevacizumab (C)
PD-L1/antiVEGF Rabbit SP142
(Ventana)
IHC 1/2/3 (IC)
Locally advanced or in metastatic renal cell carcinoma.
TC, tumor cells; IC, immuno cells in the microenvironment; SA, single agent; C,
combination of agents; IHC 1/2/3: IHC1 is ≥1%, IHC2 is ≥5%, IHC3 is ≥10%.
very impressive expression of immune-mediated genes (PD-
L1, PD-L2, CTLA4, PD-1, PRF1, GZMA, BTLA, CD8A) in
a single patient with PD-L1 expression less of 5% but >1%
who showed an impressive complete response to nivolumab.
Although no final conclusion could be resumed from this study
due to the small number of patients explored it is probably that
tumors mutational burden and non-synonymous mutations play
a different role in ccRCC as compared to other disease, however,
further large prospective trials might be necessary to confirm this
hypothesis.
It is worth mentioning the IMmotion 151 trial, a randomized
Phase III study of Atezolizumab plus Bevacizumab vs. Sunitinib
in untreated metastatic RCC (35). Primary endpoints included
PFS in PD-L1 positive patients and OS in an intention to treat
analysis. The IMmotion 151 trial met its primary PFS endpoint
in the PD-L1 positive patients with atezolizumab+ bevacizumab
compared to sunitinib with fewer high grade adverse reactions.
This data does support atezolizumab + bevacizumab as first line
therapy in metastatic clear cell renal cell (35, 56).
GENE EXPRESSION AS PREDICITVE
IMMUNOLOGICAL BIOMARKERS IN
RENAL CELL CARCINOMA
Regarding gene expression, several data seem to correlate the
expression of specific classes of genes (especially DNA repair
genes) to immunotherapy outcomes (30). Reportedly, the most
frequent event involved in ccRCC is the loss of chromosome
3p, which is associated with the development of VHL, PBRM1,
BAP1 and SETD2 alterations in about 90% of ccRCC cases.
Together with KDM5C, PTEN,MTOR and TP53, these represent
the eight most frequently altered genes in ccRCC (22, 23,
36). However, second most frequently mutated sub-network
included AID1A, SMARCA4, and PBAF SWI/SNF chromatin
remodeling complex. When mutations occur in chromatin
regulators PBRM1, BAP1, and SETD2, several related genes
showed altered expression as compared to VHL mutation (22,
23, 36). In particular, chromatin modification pathways interact
with several genes involved in hormonal activity (ESR1), RAS
oncogene, transcriptional output (HIF1A, JUN, FOS, and SP1),
TGF-beta and especially DNA repair (BAP1) and immune-
mediated signaling (NFKB1 and IL-6) (22, 23, 36). To date, no
data about the correlation between gene expressions (especially
DNA repair gene alterations and immune-related genes) are
available, but this appears to be an attractive hypothesis to test
mainly focused on the detection of predictive markers and the
better understanding of mechanisms related to immune response
in ccRCC (22, 23, 36).
The fundamental role of the gene alterations of PBMR1,
BAP1 and SETD2 has been recently enforced by the findings
presented at ASCOAnnual Meeting 2018. The Spanish Oncology
Genitourinary Group (SOGUG) presented the results of an
observational prospective study collecting samples from 77
RCC patients treated with mTOR inhibitors everolimus or
temsirolimus (79 and 21% of cases, respectively) (37). The
study analysis included both IHC for p-S6, p-S6K1, p-AKT,
p21, BAP1, and PBRM1 and NGS (next generation sequencing)
for mutational analysis on key genes of mTOR pathway in
RCC. Among enrolled patients, 87% had ccRCC histology; 60%
had intermediate, 39% good prognosis, and 1% poor prognosis
(MSKCC). No association between p-S6, p-S6K1, p-AKT, and p21
staining and response to temsirolimus/everolimus was reported.
However, negative IHC expression for BAP1 and PBRM1 was
associated with better mTOR inhibitor response (OR = 4.0,
95%CI = 1.4–11.9, p = 0.011 and OR = 3.9, 95%CI = 1.2–12.8,
p= 0.025).
On the other hand, Bossé et al. reported on the prognostic
value of genetic alterations resulting in loss of function (defined
by the presence of pathogenic gene variant or 2 copy deletion)
of VHL, PBRM1, BAP1, SETD2, TP53, and KDM5C, which are
frequently mutated in metastatic RCC, in patients with ccRCC
stratified by IMDC risk classification and treated with 1st line
VEGFR tyrosine kinase inhibitors (38). Tumor samples were
analyzed by NGS or whole exome sequencing (TCGA). Three
hundred and eight patients were included; 21% of them with
IMDC good risk features, 54% intermediate and 17% poor
risk (8% unknown). The presence of gene alterations in VHL,
PBRM1, SETD2, BAP1, TP53, and KDM5C was, respectively,
77, 43, 29, 19, 11, and 11%. Gene alterations in BAP1 were
associated with worst OS (HR 1.7; 95%CI 1.1–2.5, p= 0.01), while
alterations in PBRM1 and KDM5C were correlated with longer
OS. Patients with tumors PBRM1 wild type and harboring gene
alterations in BAP1 had worse OS (37 vs. 50 months, HR 1.9,
95% CI 1.2–2.8, p = 0.004). Interestingly, when IMDC stratified
criteria were applied the genomic profile was prognostic only in
patients with intermediate risk.
The advances in understanding the molecular landscape
of RCC parallel with the progresses in the histopathological
characterization of this neoplasm. The 2016 WHO classification
of the tumors of the kidney (13) has identified new renal entities
including hereditary leiomyomatosis and renal cell carcinoma
syndrome–associated RCC, succinate dehydrogenase–deficient
RCC, tubulocystic RCC, acquired cystic disease–associated RCC,
and clear cell papillary RCC. The list of histologic categories
includes also emerging entities, such as RCC associated with
ALK gene rearrangements and thyroid-like follicular RCC (13).
A more accurate identification of the different histological tumor
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categories represents another fundamental step forward for the
selection of molecularly targetable approaches for patients with
RCC thus enabling the possibility to selectively target the gene
drivers of specific tumor variants (13). More recently, Chen et al.
(16) surveyed 894 RCC cases for expression of genes involved
in immune checkpoint pathways, including PD1 and PDL1
genes. Clear cell RCC subtypes had relatively high expression of
several genes representing targets for immunotherapy, including
PDCD1 (PD1), CD247 (CD3), PDCD1LG2 (PDL2), CTLA4
(CD152), TNFRSF9 (CD137), and TNFRSF4 (CD134). In
addition, analysis of gene expression signatures and of DNA
methylation signatures suggested greater levels of immune cell
infiltrates, including T cells, within clear cell RCC relative to other
RCC subtypes (16, 17).
Within clear cell-enriched (CC-e) RCC genomic subtypes,
differential expression of specific checkpoint-related genes was
observed mostly involving differences between CC-e.3 and CC-
e.2 groups (more aggressive and less aggressive ccRCC categories,
respectively). Compared to CC-e.2, CC-e.3 showed increased
promoter methylation of miR-21 (MIR21) with corresponding
decreased levels of the miR-21 target PTEN. In cancer, PTEN
has an established role in intrinsic cellular control of PD-
L1 (16, 17). Some other genes—including PDCD1, CTLA4,
and TLR9—were associated with worse patient survival within
ccRCC-associated cases; PDL1 expression was correlated with
better patient survival, though this association was confounded
by copy loss of 9p region associated with aggressive clear cell RCC
and worse prognosis (18). In summary, better understanding the
predictive and prognostic significance of PD1/PD-L1 expression
and the identification of molecularly defined subtypes correlated
with survival and response to therapy, represent quick steps
toward implementing precision medicine in RCC via reducing
the distance to the goal of identifying the best approach for a
single RCC patient (28, 29, 40) (Table 3).
PD-L1 IMMUNOHISTOCHEMISTRY IN RCC
Imunocheckpoint inhibitors (ICI) have marked a new paradigm
in the treatment of RCC. The anti-PD1 drug nivolumab has
been the first ICI drug to obtain approval by the FDA and
European Commission for the treatment of RCC, and showed
a significant OS benefit in patients with RCC that progressed
following antiangiogenic therapy compared with everolimus
(mTOR inhibitor) (26). Several other ICI compounds are
currently under investigation for the treatment of RCC, alone or
in combination with TKIs or other drugs (57–59).
Predictive biomarker research to select RCC patients eligible
for ICI has mainly focussed on the PD1-PD-L1 axis detected by
means of IHC. Low-to-no expression of PD-L1 on IC (immune
cells) and TC (tumor cells) correlated with a trend toward lower
response (PFS and OS) to the anti-PD-L1 drug atezolizumab
compared with moderate to high PD-L1 expression levels (60).
Updated analysis further confirmed the association between high
PD-L1 expression and improvedOSwith atezolizumab treatment
(57). For the anti-PD1 drug nivolumab, early data suggested a
positive correlation between PD-L1 expression on TC and ORR
(61–64). Data from the Checkmate 025 trial showed that higher
levels of PD-L1 expression are associated with poorer survival
in RCC, but did not support PD-L1 as a marker predictive of
treatment benefit in RCC; a benefit was observed, however, with
nivolumab irrespective of PD-L1 expression (62). Furthermore,
PD-L1 seems to be a dynamic biomarker since prior exposure to
VEGF and mTOR inhibitors modulates its expression which can
be largely variable after therapy (64, 65). Notably, a significant
number of patients with PD-L1+ RCC do not respond to PD-
1 pathway blockade, suggesting that additional intra-tumoral
factors may influence treatment outcome (64, 65). Based on
recent data, PD-L1 could be a prognostic biomarker for the
adverse clinic-pathologic features of RCC but may not be
discriminant enough to be a predictive biomarker (64, 66,
67). Furthermore, it was found that PD-L1 staining is almost
exclusively observed in the high-grade component of a tumor and
additionally a discordant expression of PD-L1 between primary
tumors and their metastases was detected in ∼20% of cases (68).
Similar heterogeneity has been observed between primary and
metastatic tumor based on molecular analysis (69).
Other possible biomarkers like PD-L2 and CTLA4 are
reported in literature, thus far without straightforward predictive
value (57). Increased amounts of CD3+/CD8+ tumor-infiltrating
T-cells have been reported after nivolumab treatment, but further
research is needed to determine the biomarker-potential of this
observations (70).
Recent data from a gene expression study on a small cohort
of PDL1+ RCC patients treated with nivolumab identified
a metabolic gene profile in the non-responding subgroup
and overexpression of immunologic factors in the responding
subgroup (71). Increasing mutational burden and neo-antigen
formation have been associated with increased responsiveness
to ICI in several other malignancies and recent data showed
increased frequency of genomic alterations in RCC post-VEGFR
therapy (72). These findings might explain the observed benefit
of nivolumab post-VEGFR therapy and seem to correlate
with the observation of lower response rates to nivolumab
monotherapy in front line studies (70). A recent multilevel
molecular analysis on the integrated TCGA RCC database
showed relatively high expression of several genes representing
targets for immunotherapy in ccRCC-associated molecular
subtypes compared to other RCC subtypes, with additional
differences within the several clear cell-enriched RCC genomic
subtypes (16). These data also suggested greater levels of IC
infiltrates within ccRCC relative to other RCC types (16).
TCGA data suggest the hypothesis that clear cell-enriched RCC
genomic subtypes would be most responsive to targeted immune
checkpoints, hypothesis that awaits validation in prospective
cohort series (16).
Several technical and biochemical issues are involved to
explain the observed ambiguity of PD-L1 expression as predictor
of response to ICI therapy in RCC. Differences in anti-PD-
L1 antibody-clones, staining assays, tissue characteristics and
scoring systems are amongst the major technical obstacles
to overcome. The knowledge that PD-L1 expression is not
binary, but instead shows a continuum with significant
intratumour heterogeneity and therapy-induced changes, might
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TABLE 3 | Prognostic and predictive biomarkers in Renal Cell Carcinoma.
Biomarker Results Association with References
IHC expression of p-S6, p-S6K1, p-AKT, and p21 NA No association with
response to temsirolimus/everolimus
(37)
Negative IHC expression for BAP1 OR = 4.0, 95% CI = 1.4–11.9, p = 0.011 Better mTOR inhibitor response (37)
Negative IHC expression for PBRM1 OR = 3.9, 95% CI = 1.2–12.8, p = 0.025 Better mTOR inhibitor response (37)
Gene alterations in BAP1 HR 1.7; 95% CI 1.1–2.5,
p = 0.01
Worse OS (38)
Gene alterations in PBRM1 HR = 0.6; 95%CI 0.4–0.8,
p = 0.001
Better OS (38)
Gene alterations in KDM5C HR = 0.4; 95%CI 0.2–0.8,
p = 0.007
Better OS (38)
SETD2, TP53, and VHL NA (p > 0.4) Not associated with prognosis (38)
PBRM1 wild type + gene alterations BAP1 37 vs. 50 months, HR 1.9, 95% CI 1.2–2.8,
p = 0.004
Worse OS (38)
PDCD1, CTLA4, and TLR9 NA Worse OS (16)
9p deletion HR 4.323; p = 0.021
HR 4.603; p = 0.007
High risk of recurrence and
RCC-specific mortality
(18)
even represent a bigger challenge for being an ideal biomarker
(73, 74). The recent report on the presence of compensatory
inhibitory pathways (VISTA) in the setting of immunotherapy in
metastatic prostate further underlines the complexity to predict
the therapeutic response based on a single biomarker like PD-
L1 (74). Recent concordance studies on non-small cell lung
cancer have shown only minimal differences in staining patterns
between most of the different validated and commercially
available anti-PD-L1 antibody clones (73, 75–78). These findings
are encouraging, although clinical cross-validation data between
the different assays are not available at this moment. High
concordances between the different assays and between the
pathologists within a single assay were only found for PD-L1
scoring TC and not in immune cells IC (75, 76). Concerning RCC
this could be a critical point since PD-L1 expression in IC is used
as a companion biomarker for some FDA-approved anti-PD-L1
drugs.
MMR-DEFICIENCY AND MUTATIONAL
LOAD IN RCC
Renal cell carcinoma are not considered to belong to the
HNPCC (hereditary non-polyposis colon cancer) spectrum, but
in sporadic RCC loss of MMR proteins is frequently observed,
especially of MLH1 and MSH2 (79–81). Variable MMR gene
alterations have been reported as underlying mechanisms, but
others did not detect microsatellite instability (MSI) caused by
either promoter hypermethylation or alteration of the coding
region of MMR studied genes (81–83). The reduced MMR
protein expression by IHC has been linked to RCC subtypes and
might contribute to the respective different biological behavior
(84). As addressed earlier in this review, MMR-deficiency is
more and more recognized as an important biologic event in
genitourinary cancers. MMR deficiency can occur in patients
with Lynch syndrome (HNPCC) and in patients with sporadic
MMR-deficient tumors (84). MMR-deficient tumors exhibit a
higher rate of mutations (high mutational burden), which can
result in the formation of neo-antigens to enhance the antitumor
immune response (85). Furthermore, MMR-deficient tumors
express different immune checkpoint ligands indicating that
their active immune microenvironment is counterbalanced by
immune inhibitory signals that resist tumor destruction (86).
Recently reported data showing a better clinical response to
the anti-PD-1 drug pembrolizumab in MMR-deficient patients
support the hypothesis that MMR-deficient tumors respond
better to anti-PD-1 therapy than do MMR-proficient tumors
(87).
In RCC cancers, data on the relation betweenMMR-status and
response to immunotherapy are still emerging (88, 89). Based on
the promising results in patients with MMR-deficient cancers,
FDA has recently approved pembrolizumab for the treatment
of adult and pediatric patients with un-resectable or metastatic
MMR-deficient solid tumors, irrespective of the tumor origin. In
this context, MMR-deficient/MSI-H solid genitourinary tumors
could be important candidates for anti PD-1 treatment. The
reality might however be much more complex; for instance,
several clinical trials have shown that some MMR-deficient
tumors do not respond to immunotherapy, while mutations
in other genes have also been linked to high mutational
burden and upregulation of immune checkpoints (85). From a
methodological point of view, there is an ongoing discussion
and evolution in literature concerning the methodology to get
reliable data on mutational load and MSI in a context of cost-
efficiency and optimal logistics. Whole exome sequencing, T-cell
receptor sequencing and targeted NGS can be used to assess
mutational load (90) and promising data on novel platforms
to detect MSI (e.g., MSI-Sensor and MANTIS) have recently
been published (91). The detection of MMR-deficient tumors
and the selection of those patients that will really benefit
from immunotherapy remains an ongoing and challenging
task.
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BIOMARKERS OF ACQUIRED
RESISTANCE
Despite the durable responses observed with immune checkpoint
inhibition, nearly all patients will progress. A number of
mechanisms have been identified including neo-antigen loss,
upregulation of alternative immune checkpoints, loss of antigen
presentation, and defective interferon signaling (92–94). A recent
whole exome sequencing study on paired tumor samples prior
to treatment with ICI and at the time of progression (n = 4, 2
treated with nivolumab/ipilimumab, 2 treated with nivolumab)
was reported by Anagnostou et al. (92). Although they found an
increase in total number of candidate neo-antigens, a subset of
them was actually eliminated at the time of acquired resistance.
In the four patients, there were 18, 10, 7, and 6 neo-antigens
lost, and all of them had higher predicted MHC binding affinity.
There were no copy number alterations of CD274 which encodes
for PD-L1, PDCD1 encoding for PD-1, CTLA-4, JAK1, or JAK2.
There were no genetic alterations in HLA or β2-microglobulin.
They also evaluated clonal T-cell reactivity in three of these
patients using peripheral blood mononuclear cells loaded with
predicted neo-antigens cultured with purified T-cells. All patients
showed clonal T-cell expansion to lost peptides and either no
affinity or lower affinity for the wild type of the predicted neo-
antigen (92). Neo-antigen loss and growth of a subclone lacking
the neo-antigen eliciting the immune response are both potential
explanations of this resistance mechanism, although the power
of available information is limited. This mechanism of resistance
underscores the rationale for using neo-antigen profiling as a
predictive biomarker of benefit and also underscores the dynamic
nature of these biomarkers.
Defects in the interferon-γ signaling pathway have also been
identified as a major mechanism of resistance. Interferon-γ
signaling plays a crucial role in the anticancer immune response.
It has been shown to upregulate PD-L1 expression on TC and
IC, to increase MHC Class I expression and promote antigen
presentation, and recruit effector cells (92–97). It results in the
downstream stimulation of JAK/STAT signaling pathway and
expression of a number of anti-cancer genes (98). Mutations in
JAK1/2 render cells insensitive to interferon-γ signaling, which
results in escape from PD-L1 pathway inhibition and impairs
the antitumor immune response. This has been identified as
a mechanism of both primary and secondary resistance (99–
101). Interferon-γ signaling has been demonstrated to increase
expression of immune inhibitorymolecules, such as indolaimine-
2,3-deoxygenase (IDO) that can limit the anti-tumor response
(101). Inhibition of IDO production is the subject of an ongoing
clinical trial in combination with PD-1 immune checkpoint
inhibition. Defects in antigen presentation, such as mutations
in the β-2 microglobulin gene, have also been identified as a
mechanism of resistance (100). Beta-2 microglobulin is essential
for MHC class I molecule surface expression and a defect can
block CD8-Tcell recognition. HLA loss is another potential
mechanism of immune evasion and determining copy number
alterations have been difficult due to the polymorphic nature
of the locus. McGrahan et al. developed a computational tool
using NGS data to determine HLA loss of heterozygosity in
100 early stage NSCLC patients. Interestingly, 40% of patients
displayed HLA loss of heterozygosity and phylogenetic analysis
shows that this is likely a later evolutionary event (102). TIM-3,
LAG-3, and TIGIT are known alternative immune checkpoints
that play a role in T-cell exhaustion and are expressed on tumor
infiltrating lymphocytes (93). Koyama and colleagues identified
TIM-3 to be upregulated in amurinemodel of NSCLC at the time
of resistance to anti-PD-1 therapy and demonstrated a survival
advantage with treatment using a TIM-3 blocking antibody.
The authors additionally identified two patients with biopsies
performed at the time of progression to anti- PD-1 therapy
with increased TIM-3 expression (103). Novel therapeutic
approach directed at these alternative immune checkpoints are
the subject of ongoing clinical trials and are of potential relevance
in RCC.
FUTURE PERSPECTIVE
The complex interplay of signaling pathways and inflammatory
mediators seems to be crucial for RCC development and
response to therapy (43, 44, 53). Immune cells including
neutrophils, lymphocytes andmacrophages have been implicated
in promoting metastatic spread, tumor angiogenesis, in primary
and acquired drug resistance, as well as in the formation of pre-
metastatic niches (43, 44, 53). On this scenario, the checkpoint
molecules have gained wide interest since the introduction of
anti-CTLA-4 and anti-PD-1/PD-L1 agents into daily oncology
practice (45). Beyond PD-1 and CTLA-4, a variety of molecules
are emerging as potentially future therapeutic immunotargets
in RCC (46). This list includes the V-domain immunoglobulin
containing suppressor of T-cell activation (VISTA), which
has been recently shown to exert its inhibitory activity by
acting as a ligand on antigen presenting cells and as a
receptor on T cells (104–106), chemokine receptors (45), the
soluble lymphocyte-activation gene-3 (LAG-3), 4-1BB, B and T
lymphocyte attenuator, and OX40 (CD134) (47).
Nowadays, there is not a clear-cut knowledge of the
underlying mechanisms of immuno-checkpoint inhibitors-
induced tumor response. To address this issue, Wei et al.
investigated the effects of anti-PD-1 and anti-CTLA-4 inhibitors
in human melanoma and murine tumor models (48). They first
revealed that these agents are able to target distinct tumor-
infiltrating T cell subpopulations. In particular, PD-1 blockade
promotes the expansion of specific exhausted-like CD8-T cell
population, while CTLA-4 blockade induces both an ICOS+
Th1-like CD4 effector subset and exhausted-like CD8-T cells
(48). This evidence favors the combined use of current and
probably future checkpoint inhibitors in cancer patients. These
combinations, seems to be characterized by a tolerable safety
profile (107). Tumor responsiveness may vary according to the
mutational load and the expression of immunotargets in the
tumor environment, which is variable in the different phases
of RCC development and progression (49, 108–110). Based on
this evidence, assessing the expression of PD-1/PD-L1 or other
emerging immunotargets only at the diagnosis of metastatic
disease may not reflect tumor dynamicity.
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To improve the feasibility and reduce the clinical impact of re-
biopsy, assessing biomarkers on circulating tumor cells (CTCs)
or exosomes (111) may represent a not invasive strategy that
can be performed several times during cancer therapy in order
to reflect the changes occurred in the tumor environment. An
early identification of validated biomarkers would be crucial
to definitively place immunotherapy into the era of precision
medicine and to optimize the cost-effectiveness of ICI agents
in cancer patients (50, 112). In addition, the recent paper by
Routy et al. showed that primary resistance to ICI can be
correlated with abnormal gut microbiome composition (51). In
this study, the effectiveness of PD-1 blockade resulted enhanced
by transplanting fecal microbiota from responder cancer patients
into germ-free or antibiotic-treated mice (51), thus representing
another step forward on the way to personalized and precision
immunotherapy in cancer patients.
Another factor that results of great relevance to improve
the efficacy of ICI in RCC patients is the comprehension of
the immunological effects of TKIs and mTOR inhibitors (53,
113). Actually, these agents can indirectly exert their anti-tumor
activity by targeting immune cells in the RCCmicroenvironment
(53), and this should be considered in order to combine or
sequence them with currently available and probably future
immunotherapies. For instance, sunitinib has been shown to
inhibit the colony forming units driven by GM-CSF and FLT3
ligand FLT3L (114) as well as dendritic cell antigen-presentation
(115) (by decreasing the secretion of cytokines and the expression
of MHC and CD1a molecules), to suppress the myeloid-derived
suppressor cells (MDSCs are involved in RCC progression
and drug resistance), to enhance tumor cell sensitivity to NK
cell killing (116) and to reduce the total count of CD3 and
CD4T cells and regulatory T cells (117, 118). On the other
hand, pazopanib showed lower inhibitory potency and affinity
against FLT3 and c-kit compared to sunitinib (119). Interestingly,
we previously showed that axitinib can increase the surface
NKG2D ligand expression, thus promoting NK cell recognition
and degranulation in A-498 RCC cells in a ROS-dependent
manner (120). At present, few evidences are available on
the immunomodulatory effects of cabozantinib and lenvatinib,
recently introduced into RCC clinical practice.
EXPERT OPINION AND CONCLUSIONS
Optimizing the combination between immunotherapy and target
agents as well as the possible favorable sequence of treatment
between these two classes of drugs remain open questions at
this moment but ongoing studies support this as of great future
potential. On this way we have only limited data provided from
Immotion150 which demonstrated that association between a
PD-L1 inhibitor and bevacizumab is feasible, well-tolerated, and
results in an effective clinical benefit from our patients. Of
relevance, is to note that most studies explored immunotherapy
in patients with ccRCC and the role of ICI still remains
unknown in mccRCC. Though, there are several questions that
need to be answered, current data support that immunotherapy
represents a revolution for the management of RCC resulting
in a dynamic and evolving scenario in which more novelties
will be shortly made available. Because the potentially deadly
adverse effects from immune checkpoint inhibitors, gathering
predictive information in RCC seems to be prudent. However,
recent scientific insights indicate that a single biomarker for
patient selection may not be feasible, given that immune
responses are dynamic and evolve over time (121). Biomarker
development for ICI drugs will require integration of multiple
biologic components like PD-L1 expression, TILs, mutational
load, and probably many others now considered emergent
biomarkers.
EXECUTIVE SUMMARY
• Immunotherapy is gradually becoming a key factor in the
therapeutic algorithm for patients with renal cell cancers at
different stages of disease.
• The increasing knowledge on the genomic landscape of renal
cell carcinoma supports stratification of patients for targeted
therapies.
• A single biomarker for patient selection may not be feasible,
given that immune responses are complex, dynamic and
evolve over time.
• Biomarker development for ICI drugs will require integration
of multiple biologic components like PD-L1 expression, TILs
and mutational load.
NEXT STEPS
• New methodological approaches likely based on digital
pathology may be relevant since they allow objectively
recognizing and quantitation of the biomarker and therefore
might produce objective and reproducible cut-offs useful in
patient’s therapeutic stratification.
• Radiologic derived biomarkers, such as artificial intelligence
derived, radiopharmaceutic, and liquid biopsy derived
biomarkers, are likely to enter the biomarker-field in the next
coming years.
• Large-scale biomarker-driven prospective trials with
consensus methodologies on biomarker assessment and
scoring are needed to reach clinical validation of different
biomarkers, needed for a reliable single-patient appointment
to the appropriate immunotherapy.
• Multidisciplinary approaches are needed to fully develop the
current and future value of ICI in clinical practice.
• Better understanding of solid tumor genomics shows that
also for RCC, combining targeted therapy with ICI has
the potential to improve cancer outcomes, and that reliable
biomarkers will be crucial for a stringent patient selection
in trials of targeted and checkpoint inhibitor drugs and to
apply novel therapeutic strategies aimed at restoring effective
antitumor immunity in patients with cancer.
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